The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

Are we focused on the wrong risk type in genetic screening?

Breast cancer screening study shows new paths to population screening

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

A common perception of genetic screening is that only individuals at high risk of certain diseases will be identified. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Cassie Hajek, MD
Medical director, Helix
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM. 
In Brief

KU Cancer Center deploys new mobile cancer screening bus

The University of Kansas Cancer Center and its outreach network, the Masonic Cancer Alliance, announced a new effort to provide cancer screening throughout the cancer center’s catchment area. Known as HOPE on Wheels: Health, Outreach, Prevention, and Education, a 42-foot bus will help ensure that geography isn’t a barrier to detecting cancers earlier.
Byline
Cassie Hajek, MD
Medical director, Helix
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account